|Table of Contents|

The value of abdominal adipose tissue,labial gland and bone marrow combined with LMD/MS in the diagnosis of light chain amyloidosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2890-2894
Research Field:
Publishing date:

Info

Title:
The value of abdominal adipose tissue,labial gland and bone marrow combined with LMD/MS in the diagnosis of light chain amyloidosis
Author(s):
SONG Lijun1; SONG Lifeng2; XUE Yimiao1; SU Yan1; CHEN Junmin1; BAO Shen1; WEI Yuping1
1.People's Hospital of Ningxia Hui Autonomous Region，First Affiliated Hospital of Northwest University for Nationalities，Ningxia Yinchuan 750002，China;2.People's Hospital of Guyuan Yuanzhou Region，Ningxia Guyuan 756000，China．
Keywords:
light chain amyloidosis; adipose tissue; labial glands; bone marrow; Congo red stain; LMD/MS
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2023.15.023
Abstract:
Objective:To analyze the application of abdominal adipose tissue biopsy,labial gland biopsy and bone marrow biopsy in the diagnosis of light chain amyloidosis（AL）,to evaluate the clinical value of 3 minimally invasive biopsy methods in patients with different organ involvement and the significance of 3-site combined biopsy in improving the positive rate of diagnosis.Methods:Retrospectively analyzed the clinical data of 61 patients which were diagnosed in our hospital between January 2017 and September 2022,to analyze the positive rate of 3 sites minimally invasive biopsy,organ involvement and the results of different sites biopsy,laser microdissection combined with mass spectrometry (LMD/MS） analysis was performed in January 2018 of Congo red stain positive cases in any sites.Results:Of 40 patients who underwent adipose tissue biopsy,labial gland biopsy and bone marrow biopsy,36(90%) patients were positive in at least one part,and the positive rate of LMD/MS was 100% in the positive part of Congo red stain.Conclusion:Three-site minimally invasive biopsy can significantly improve the diagnostic rate of light chain amyloidosis,LMD/MS technology can finally play a qualitative role in the type of amyloidosis.It is suggested that subcutaneous adipose tissue,labial gland and bone marrow biopsy should be performed in patients with suspected AL and confirmed by LMD/MS.

References:

［1］中国系统性轻链型淀粉样变性协作组，国家肾脏疾病临床医学研究中心，国家血液系统疾病临床医学研究中心.系统性轻链型淀粉样变性诊断和治疗指南（2021年修订）［J］.中华医学杂志，2021，101(22):1646-1656. Chinese Cooperative Group on Systemic Light Chain Amyloidosis,National Center for Clinical Medical Research of Kidney Disease,National Center for Clinical Medical Research of Hematological Diseases.Guidelines for the diagnosis and treatment of systemic light chain amyloidosis (2021 revision) ［J］.Chinese Medical Journal,2021,101(22):1646-1656.
［2］MERLINI G,DISPENZIERI A,SANCHORAWALA V,et al.Systemic immunoglobulin light chain amyloidosis［J］.Nature Reviews Disease Primers，2018，4(1):38.
［3］HASIB SIDIQI M,GERTZ MA.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021［J］.Blood Cancer Journal，2021，11(5):90.
［4］GERTZ MA,LACY MQ,DISPENZIERI A,et al.Autologous stem cell transplant for immunoglobulin light chain amyloidosis:a status report［J］.Leukemia & Lymphoma，2010，51(12):2181-2187.
［5］徐天虹,魏征,陈晨,等.腹壁脂肪与唇腺活检联合诊断轻链型淀粉样变性的价值［J］.中国临床医学,2019,26(01):37-42. XU TH,WEI Z,CHEN C,et al.The value of abdominal wall fat combined with labial gland biopsy in the diagnosis of light chain amyloidosis ［J］ .Chinese Medical Journal,2019,26(01):37-42.
［6］KUMAR SK,CALLANDER NS,ADEKOLA K,et al.Systemic light chain amyloidosis,version 2.2023,NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network，2023，21(1):67-81.
［7］DISPENZIERI A,GERTZ MA,KYLE RA,et al.Serum cardiac troponins and N-terminal pro-brain natriuretic peptide:a staging system for primary systemic amyloidosis［J］.Journal of Clinical Oncology，2004，22(18):3751-3757.
［8］ARIKE L,PEIL L.Spectral counting label- free proteomics［J］.Methods in Molecular Biology,2014,1156:213-222.
［9］VAXMAN I,GERTZ M.When to suspect a diagnosis of amyloidosis［J］.Acta Haematologica,2020,143(4):304-311.
［10］LOUSADA I,COMENZO RL,LANDAU H,et al.Light chain amyloidosis:patient experience survey from the amyloidosis research consortium［J］.Advances in Therapy,2015,32(10):920-928.
［11］GERTZ MA.Cardiac amyloidosis［J］.Heart Failure Clinics，2022，18(3):479-488.
［12］KOIKE H,MOURI N,FUKAMI Y,et al.Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis［J］.Journal of the Neurological Sciences，2021，421:117305.
［13］HASIB SIDIQI M,GERTZ MA.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021［J］.Blood Cancer Journal，2021，11(5):90.
［14］MUCHTAR E.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014:cracking the glass ceiling of early death［J］.Blood，2017，129:2111-2119.
［15］BAKER KR.Light chain amyloidosis:Epidemiology,staging,and prognostication［J］.Methodist DeBakey Cardiovascular Journal，2022，18(2):27-35.
［16］GERTZ MA.Immunoglobulin light chain amyloidosis:2022 update on diagnosis,prognosis,and treatment［J］.American Journal of Hematology，2022，97(6):818-829.
［17］ABILDGAARD N,ROJEK AM,MLLER HE,et al.Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits［J］.Amyloid，2020，27(1):59-66.

Memo

Memo:
宁夏回族自治区人民医院培育振兴项目(编号：201917）
Last Update: 2023-06-30